Xpert MTB/RIF Ultra assay for tuberculosis disease and rifampicin resistance in children
Alexander W Kay, Tara Ness, Sabine E Verkuijl, Kerri Viney, Annemieke Brands, Tiziana Masini, Lucia González Fernández, Michael Eisenhut, Anne K Detjen, Anna M Mandalakas, Karen R Steingart, Yemisi Takwoingi, Alexander W Kay, Tara Ness, Sabine E Verkuijl, Kerri Viney, Annemieke Brands, Tiziana Masini, Lucia González Fernández, Michael Eisenhut, Anne K Detjen, Anna M Mandalakas, Karen R Steingart, Yemisi Takwoingi
Abstract
Background: Every year, an estimated one million children and young adolescents become ill with tuberculosis, and around 226,000 of those children die. Xpert MTB/RIF Ultra (Xpert Ultra) is a molecular World Health Organization (WHO)-recommended rapid diagnostic test that simultaneously detects Mycobacterium tuberculosis complex and rifampicin resistance. We previously published a Cochrane Review 'Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for tuberculosis disease and rifampicin resistance in children'. The current review updates evidence on the diagnostic accuracy of Xpert Ultra in children presumed to have tuberculosis disease. Parts of this review update informed the 2022 WHO updated guidance on management of tuberculosis in children and adolescents.
Objectives: To assess the diagnostic accuracy of Xpert Ultra for detecting: pulmonary tuberculosis, tuberculous meningitis, lymph node tuberculosis, and rifampicin resistance, in children with presumed tuberculosis. Secondary objectives To investigate potential sources of heterogeneity in accuracy estimates. For detection of tuberculosis, we considered age, comorbidity (HIV, severe pneumonia, and severe malnutrition), and specimen type as potential sources. To summarize the frequency of Xpert Ultra trace results.
Search methods: We searched the Cochrane Infectious Diseases Group Specialized Register, MEDLINE, Embase, three other databases, and three trial registers without language restrictions to 9 March 2021.
Selection criteria: Cross-sectional and cohort studies and randomized trials that evaluated Xpert Ultra in HIV-positive and HIV-negative children under 15 years of age. We included ongoing studies that helped us address the review objectives. We included studies evaluating sputum, gastric, stool, or nasopharyngeal specimens (pulmonary tuberculosis), cerebrospinal fluid (tuberculous meningitis), and fine needle aspirate or surgical biopsy tissue (lymph node tuberculosis). For detecting tuberculosis, reference standards were microbiological (culture) or composite reference standard; for stool, we also included Xpert Ultra performed on a routine respiratory specimen. For detecting rifampicin resistance, reference standards were drug susceptibility testing or MTBDRplus.
Data collection and analysis: Two review authors independently extracted data and, using QUADAS-2, assessed methodological quality judging risk of bias separately for each target condition and reference standard. For each target condition, we used the bivariate model to estimate summary sensitivity and specificity with 95% confidence intervals (CIs). We stratified all analyses by type of reference standard. We summarized the frequency of Xpert Ultra trace results; trace represents detection of a very low quantity of Mycobacterium tuberculosis DNA. We assessed certainty of evidence using GRADE.
Main results: We identified 14 studies (11 new studies since the previous review). For detection of pulmonary tuberculosis, 335 data sets (25,937 participants) were available for analysis. We did not identify any studies that evaluated Xpert Ultra accuracy for tuberculous meningitis or lymph node tuberculosis. Three studies evaluated Xpert Ultra for detection of rifampicin resistance. Ten studies (71%) took place in countries with a high tuberculosis burden based on WHO classification. Overall, risk of bias was low. Detection of pulmonary tuberculosis Sputum, 5 studies Xpert Ultra summary sensitivity verified by culture was 75.3% (95% CI 64.3 to 83.8; 127 participants; high-certainty evidence), and specificity was 97.1% (95% CI 94.7 to 98.5; 1054 participants; high-certainty evidence). Gastric aspirate, 7 studies Xpert Ultra summary sensitivity verified by culture was 70.4% (95% CI 53.9 to 82.9; 120 participants; moderate-certainty evidence), and specificity was 94.1% (95% CI 84.8 to 97.8; 870 participants; moderate-certainty evidence). Stool, 6 studies Xpert Ultra summary sensitivity verified by culture was 56.1% (95% CI 39.1 to 71.7; 200 participants; moderate-certainty evidence), and specificity was 98.0% (95% CI 93.3 to 99.4; 1232 participants; high certainty-evidence). Nasopharyngeal aspirate, 4 studies Xpert Ultra summary sensitivity verified by culture was 43.7% (95% CI 26.7 to 62.2; 46 participants; very low-certainty evidence), and specificity was 97.5% (95% CI 93.6 to 99.0; 489 participants; high-certainty evidence). Xpert Ultra sensitivity was lower against a composite than a culture reference standard for all specimen types other than nasopharyngeal aspirate, while specificity was similar against both reference standards. Interpretation of results In theory, for a population of 1000 children: • where 100 have pulmonary tuberculosis in sputum (by culture): - 101 would be Xpert Ultra-positive, and of these, 26 (26%) would not have pulmonary tuberculosis (false positive); and - 899 would be Xpert Ultra-negative, and of these, 25 (3%) would have tuberculosis (false negative). • where 100 have pulmonary tuberculosis in gastric aspirate (by culture): - 123 would be Xpert Ultra-positive, and of these, 53 (43%) would not have pulmonary tuberculosis (false positive); and - 877 would be Xpert Ultra-negative, and of these, 30 (3%) would have tuberculosis (false negative). • where 100 have pulmonary tuberculosis in stool (by culture): - 74 would be Xpert Ultra-positive, and of these, 18 (24%) would not have pulmonary tuberculosis (false positive); and - 926 would be Xpert Ultra-negative, and of these, 44 (5%) would have tuberculosis (false negative). • where 100 have pulmonary tuberculosis in nasopharyngeal aspirate (by culture): - 66 would be Xpert Ultra-positive, and of these, 22 (33%) would not have pulmonary tuberculosis (false positive); and - 934 would be Xpert Ultra-negative, and of these, 56 (6%) would have tuberculosis (false negative). Detection of rifampicin resistance Xpert Ultra sensitivity was 100% (3 studies, 3 participants; very low-certainty evidence), and specificity range was 97% to 100% (3 studies, 128 participants; low-certainty evidence). Trace results Xpert Ultra trace results, regarded as positive in children by WHO standards, were common. Xpert Ultra specificity remained high in children, despite the frequency of trace results.
Authors' conclusions: We found Xpert Ultra sensitivity to vary by specimen type, with sputum having the highest sensitivity, followed by gastric aspirate and stool. Nasopharyngeal aspirate had the lowest sensitivity. Xpert Ultra specificity was high against both microbiological and composite reference standards. However, the evidence base is still limited, and findings may be imprecise and vary by study setting. Although we found Xpert Ultra accurate for detection of rifampicin resistance, results were based on a very small number of studies that included only three children with rifampicin resistance. Therefore, findings should be interpreted with caution. Our findings provide support for the use of Xpert Ultra as an initial rapid molecular diagnostic in children being evaluated for tuberculosis.
Conflict of interest statement
AK has conducted prior primary research on tuberculosis diagnostics. The Baylor College of Medicine Children's Foundation‐Swaziland, where Dr Kay is based, received a discount from Cepheid on Xpert MTB/RIF Ultra cartridges for a tuberculosis case finding programme. The Baylor College of Medicine Children's Foundation‐Eswatini is separate from Baylor College of Medicine (AK's employer).
TN has no known conflicts of interest.
SEV is a Medical Officer at the World Health Organization Global Tuberculosis Programme, which commissioned this review update for the 2022 WHO consolidated guidelines on the management of tuberculosis in children and adolescents.
KV is a WHO staff member.
AB works as a technical officer at the WHO Global Tuberculoiss Programme, which commissioned this review update for the 2022 WHO consolidated guidelines on the management of tuberculosis in children and adolescents.
TM is a consultant to the WHO.
LGF has no known conflicts of interest.
ME is a CIDG Editor, and has no known conflicts of interest.
AKD has conducted prior primary research on tuberculosis diagnostics and has no known conflicts of interest. She works for UNICEF, and in her role as child health specialist is sometimes involved in developing recommendations for diagnostic approaches to detect childhood illnesses.
AMM has conducted prior primary research on tuberculosis diagnostics and has no known conflicts of interest. She has undertaken work as an independent contractor for Janssen Global Services, Medscape Independent Contractor, and Oxford Immunotec Inc.
KRS has received financial support for the preparation of systematic reviews and educational materials, consultancy fees from the Foundation for Innovative New Diagnostics (FIND) (for the preparation of systematic reviews), honoraria, and travel support to attend WHO guidelines meetings. KRS is a CIDG and DTA Editor.
YT is a Cochrane Editorial Board Member; a CIDG and DTA Editor; and a Statistical Editor for the Cochrane Bone Joint and Muscle Trauma Group.
The authors alone are responsible for the views expressed in this article and they do not necessarily represent the views, decisions or policies of the institutions with which they are affiliated.
Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
Figures
References
References to studies included in this review Barcellini 2019 {published data only}
- Barcellini L, Borroni E, Cimaglia C, Girardi E, Matteelli A, Marchese V, et al. App-based symptoms screening with Xpert MTB/RIF Ultra assay used for active tuberculosis detection in migrants at point of arrivals in Italy: the E-DETECT TB intervention analysis. PLOS One 2019;14(7):e0218039.
- Jaganath D, Wambi P, Reza TF, Nakafeero J, Aben EO, Kiconco E, et al. A prospective evaluation of Xpert MTB/RIF Ultra for childhood pulmonary tuberculosis in Uganda. Journal of the Pediatric Infectious Diseases Society 2021;10(5):586-92.
- Kabir S, Rahman SM, Ahmed S, Islam MS, Banu RS, Shewade HD, et al. Xpert Ultra assay on stool to diagnose pulmonary tuberculosis in children. Clinical Infectious Diseases 2020;73(2):226-34.
- Liu XH, Xia L, Song B, Wang H, Qian XQ, Wei JH, et al. Stool-based Xpert MTB/RIF Ultra assay as a tool for detecting pulmonary tuberculosis in children with abnormal chest imaging: a prospective cohort study. Journal of Infection 2021;82(1):84-9.
- NCT04121026. Validation of a tuberculosis treatment decision algorithm in HIV-infected children (TB-Speed HIV). (first received 9 October 2019).
- NCT04203628. Evaluation of four stool processing methods combined with Xpert MTB/RIF Ultra for diagnosis of intrathoracic paediatric tuberculosis. (first received 18 December 2019).
- NCT04240990. Development of a diagnostic prediction score for tuberculosis in hospitalized children with severe acute malnutrition (TB-Speed SAM). (first received 27 January 2020).
- NCT04899076. Stool Processing Kit (SPK) evaluation for paediatric TB. (first received 24 May 2021).
- Nicol MP, Workman L, Prins M, Bateman L, Ghebrekristos Y, Mbhele S, et al. Accuracy of Xpert MTB/RIF Ultra for the diagnosis of pulmonary tuberculosis in children. Paediatric Infectious Disease Journal 2018;37(10):e261-3.
- Parigi S, Venturini E, Galli L, Chiappini E. Xpert MTB/RIF Ultra performance in diagnosing paediatric pulmonary TB in gastric aspirates. International Journal of Tuberculosis and Lung Disease 2021;25(1):75-7.
- Sabi I, Rachow A, Mapamba D, Clowes P, Ntinginya NE, Sasamalo M, et al. Xpert MTB/RIF Ultra assay for the diagnosis of pulmonary tuberculosis in children: a multicentre comparative accuracy study. Journal of Infection 2018;77(4):321-7.
- Ssengooba W, Dieu Iragena J, Nakiyingi L, Mujumbi S, Wobudeya E, Mboizi R, et al. Accuracy of Xpert Ultra in diagnosis of pulmonary tuberculosis among children in Uganda: a substudy from the SHINE trial. Journal of Clinical Microbiology 2020;58(9):e00410-20.
- Sun L, Zhu Y, Fang M, Shi Y, Peng X, Liao Q, et al. Evaluation of Xpert MTB/RIF Ultra assay for diagnosis of childhood tuberculosis: a multicenter accuracy study. Journal of Clinical Microbiology 2020;58(9):e00702-20.
- Zar HJ, Workman LJ, Prins M, Bateman LJ, Mbhele SP, Whitman CB, et al. Tuberculosis diagnosis in children using Xpert Ultra on different respiratory specimens. American Journal of Respiratory and Critical Care Medicine 2019;200(12):1531-8. [DOI: 10.1164/rccm.201904-0772OC]
- Ali RH, Ibrahim NY, Elegail AM, Eltohami NA, Ebraheem RS, Ahmed SF, et al. Evaluation of GeneXpert MTB/RIF and line probe assay for rapid diagnosis of Mycobacterium tuberculosis in Sudanese pulmonary TB patients. Asian Pacific Journal of Tropical Disease 2017;7(7):426-9.
- Atashi S, Izadi B, Jalilian S, Madani SH, Farahani A, Mohajeri P. Evaluation of GeneXpert MTB/RIF for determination of rifampicin resistance among new tuberculosis cases in west and northwest Iran. New Microbes and New Infections 2017;19:117-20.
- Atehortúa Muñoz SL, Muñoz JR, Cárdenas Moreno SV, Ferreira CA, Cornejo Ochoa JW. Xpert MTB/RIF as a diagnostic tool in a cohort of children under 15 years of age with clinical suspicion of pulmonary tuberculosis in a hospital of high complexity in Medellin [Xpert MTB/RIF® como herramienta diagnóstica en una cohorte de niños menores de 15 años con sospecha clínica de tuberculosis pulmonar en un hospital de alta complejidad de Medellín]. Infectio 2017;21(1):25-31.
- Azevedo RG, Dinallo FS, De Laurentis LS, Boulware DR, Vidal JE. Xpert MTB/RIF® assay for the diagnosis of HIV-related tuberculous meningitis in Sao Paulo, Brazil. International Journal of Tuberculosis and Lung Disease 2018;22(6):706-7.
- Ballif M, Renner L, Claude Dusingize J, Leroy V, Ayaya S, Wools-Kaloustian K, et al. Tuberculosis in pediatric antiretroviral therapy programs in low- and middle-income countries: diagnosis and screening practices. Journal of the Pediatric Infectious Diseases Society 2015;4(1):30-8.
- Banada PP, Naidoo U, Deshpande S, Karim F, Flynn JL, O'Malley M, et al. A novel sample processing method for rapid detection of tuberculosis in the stool of pediatric patients using the Xpert MTB/RIF assay. PLOS One 2016;11(3):e0151980.
- Biadglegne F, Mulu A, Rodloff AC, Sack U. Diagnostic performance of the Xpert MTB/RIF assay for tuberculous lymphadenitis on fine needle aspirates from Ethiopia. Tuberculosis (Edinburgh, Scotland) 2014;94(5):502-5.
- Bojang AL, Mendy FS, Tientcheu LD, Otu J, Antonio M, Kampmann B, et al. Comparison of TB-LAMP, GeneXpert MTB/RIF and culture for diagnosis of pulmonary tuberculosis in The Gambia. Journal of Infection 2016;72(3):332-7.
- Che NY, Huang SJ, Ma Y, Han Y, Liu ZC, Zhang C, et al. Comparison of histological, microbiological, and molecular methods in diagnosis of patients with TBLN having different anti-TB treatment background. Biomedical and Environmental Sciences 2017;30(6):418-25.
- Cox HS, Mbhele S, Mohess N, Whitelaw A, Muller O, Zemanay W, et al. Impact of Xpert MTB/RIF for TB diagnosis in a primary care clinic with high TB and HIV prevalence in South Africa: a pragmatic randomised trial. PLOS Medicine 2014;11(11):e1001760.
- Cross GB, Coles K, Nikpour M, Moore OA, Denholm J, McBryde ES, et al. TB incidence and characteristics in the remote gulf province of Papua New Guinea: a prospective study. BMC Infectious Diseases 2014;14:93.
- Diallo AB, Kollo AI, Camara M, Lo S, Ossoga GW, Mbow M, et al. Performance of GeneXpert MTB/RIF in the diagnosis of extrapulmonary tuberculosis in Dakar: 2010–2015 [Performance du GeneXpert MTB/RIF ® dans le diagnostic de la tuberculose extra-pulmonaire à Dakar: 2010–2015]. Pan African Medical Journal 2016;25:129.
- DiNardo AR, Detjen A, Ustero P, Ngo K, Bacha J, Mandalakas AM. Culture is an imperfect and heterogeneous reference standard in pediatric tuberculosis. Tuberculosis (Edinburgh, Scotland) 2016;101S:S105-8.
- DiNardo AR, Kay AW, Maphalala G, Harris NM, Fung C, Mtetwa G, et al. Diagnostic and treatment monitoring potential of a stool-based quantitative polymerase chain reaction assay for pulmonary tuberculosis. American Journal of Tropical Medicine and Hygiene 2018;99(2):310-6.
- Ejeh EF, Undiandeye A, Akinseye VO, Okon KO, Kazeem HM, Kudi CA, et al. Diagnostic performance of GeneXpert and Ziehl-Neelson microscopy in the detection of tuberculosis in Benue State, Nigeria. Alexandria Journal of Medicine 2018;54(4):529-33.
- Gautam H, Agrawal SK, Verma SK, Singh UB. Cervical tuberculous lymphadenitis: clinical profile and diagnostic modalities. International Journal of Mycobacteriology 2018;7(3):212-6.
- Gelalcha AG, Kebede A, Mamo H. Light-emitting diode fluorescent microscopy and Xpert MTB/RIF® assay for diagnosis of pulmonary tuberculosis among patients attending Ambo hospital, west-central Ethiopia. BMC Infectious Diseases 2017;17(1):613.
- Geleta DA, Megerssa YC, Gudeta AN, Akalu GT, Debele MT, Tulu KD. Xpert MTB/RIF assay for diagnosis of pulmonary tuberculosis in sputum specimens in remote health care facility. BMC Microbiology 2015;15:220.
- Ghariani A, Jaouadi T, Smaoui S, Mehiri E, Marouane C, Kammoun S, et al. Diagnosis of lymph node tuberculosis using the GeneXpert MTB/RIF in Tunisia. International Journal of Mycobacteriology 2015;4(4):270-5.
- Giang DC, Duong TN, Ha DTM, Nhan HT, Wolbers M, Nhu NTQ, et al. Prospective evaluation of GeneXpert for the diagnosis of HIV-negative pediatric TB cases. BMC Infectious Diseases 2015;15:70.
- Guajardo-Lara CE, Saldaña-Ramírez MI, Hernández-Galván NN, Dimas-Adame MA, Ayala-Gaytán JJ, Valdovinos-Chávez SB. MGIT and other methods for diagnosing tuberculosis in a private hospital system with low incidence [MGIT y otros métodos para diagnosticar tuberculosis en un sistema hospitalario privado con baja incidencia]. Revista Médica del Instituto Mexicano del Seguro Social 2018;56(2):158-62.
- Gulla KM, Gunathilaka G, Jat KR, Sankar J, Karan M, Lodha R, et al. Utility and safety of endobronchial ultrasound-guided transbronchial needle aspiration and endoscopic ultrasound with an echobronchoscope-guided fine needle aspiration in children with mediastinal pathology. Pediatric Pulmonology 2019;54(6):881-5.
- Hakim J, Musiime V, Szubert AJ, Mallewa J, Siika A, Agutu C, et al. Enhanced prophylaxis plus antiretroviral therapy for advanced HIV infection in Africa. New England Journal of Medicine 2017;377(3):233-45.
- Helb D, Jones M, Story E, Boehme C, Wallace E, Ho K, et al. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. Journal of Clinical Microbiology 2010;48(1):229-37.
- Horo K, N'Guessan R, Koffi MO, Kouamé-N'Takpé N, Koné A, Samaké K, et al. Use of the Xpert® MTB/RIF test in routine screening of new cases of pulmonary tuberculosis in an endemic area. Revue des Maladies Respiratoires 2017;4(7):749-57.
- Huh HJ, Jeong B-H, Jeon K, Koh W-J, Ki C-S, Lee NY. Performance evaluation of the Xpert MTB/RIF assay according to its clinical application. BMC Infectious Diseases 2014;14:589.
- Kuyinu YA, Odugbemi BA, Salisu-Olatunji SO, Adepoju FO, Odusanya OO. Characteristics of Mycobacterium tuberculosis positive patients screened for drug-resistant tuberculosis at a tertiary health facility in Lagos, Nigeria. Journal of the National Medical Association 2018;110(1):88-91.
- Lopez AL, Aldaba JG, Morales-Dizon M, Sarol JN, Daag JV, Ama MC, et al. Urine Xpert MTB/RIF for the diagnosis of childhood tuberculosis. International Journal of Infectious Diseases 2019;79:44-6.
- Lu J, Li H, Dong F, Shi J, Yang H, Han S, et al. The feasibility of Xpert MTB/RIF testing to detect rifampicin resistance among childhood tuberculosis for prevalence surveys in Northern China. BioMed Research International 2017;2017:5857369.
- Lu Y, Zhu Y, Shen N, Tian L, Sun Z. Evaluating the diagnostic accuracy of the Xpert MTB/RIF assay on bronchoalveolar lavage fluid: a retrospective study. International Journal of Infectious Diseases 2018;71:14-9.
- Malik AA, Amanullah F, Codlin AJ, Siddiqui S, Jaswal M, Ahmed JF, et al. Improving childhood tuberculosis detection and treatment through facility-based screening in rural Pakistan. International Journal of Tuberculosis and Lung Disease 2018;22(8):851-7.
- Marcy O, Tejiokem M, Msellati P, Truong Huu K, Do Chau V, Tran Ngoc D, et al. Mortality and its determinants in antiretroviral treatment-naive HIV-infected children with suspected tuberculosis: an observational cohort study. Lancet HIV 2018;5(2):e87-95.
- Masenga SK, Mubila H, Hamooya BM. Rifampicin resistance in mycobacterium tuberculosis patients using GeneXpert at Livingstone Central Hospital for the year 2015: a cross sectional explorative study. BMC Infectious Diseases 2017;17(1):640.
- Mekonnen F, Tessema B, Moges F, Gelaw A, Eshetie S, Kumera G. Multidrug resistant tuberculosis: prevalence and risk factors in districts of Metema and West Armachiho, Northwest Ethiopia. BMC Infectious Diseases 2015;15:461.
- Memon SS, Sinha S, Sharma SK, Kabra SK, Lodha R, Soneja M. Diagnostic accuracy of Xpert Mtb/Rif assay in stool samples in intrathoracic childhood tuberculosis. Journal Tuberculosis and Therapeutics 2018;3(2):115.
- Metaferia Y, Seid A, Fenta GM, Gebretsadik D. Assessment of extrapulmonary tuberculosis using Gene Xpert MTB/RIF assay and fluorescent microscopy and its risk factors at Dessie referral hospital, Northeast Ethiopia. BioMed Research International 2018;2018:8207098.
- Mijovic H, Al-Nasser Y, Al-Rawahi G, Roberts A. Experience with using rapid molecular testing in diagnosing pulmonary and extra-pulmonary pediatric tuberculosis in a non-endemic setting – a retrospective case series. Paediatrics and Child Health (Canada) 2018;23(Suppl 1):e44-5.
- Modi S, Cavanaugh JS, Shiraishi RW, Alexander HL, McCarthy KD, Burmen B, et al. Performance of clinical screening algorithms for tuberculosis intensified case finding among people living with HIV in Western Kenya. PLOS One 2016;11(12):e0167685.
- Mulenga H, Tameris MD, Luabeya KK, Geldenhuys H, Scriba TJ, Hussey GD, et al. The role of clinical symptoms in the diagnosis of intrathoracic tuberculosis in young children. Pediatric Infectious Disease Journal 2015;34(11):1157-62.
- Naidoo P, Dunbar R, Lombard C, du Toit E, Caldwell J, Detjen A, et al. Comparing tuberculosis diagnostic yield in smear/culture and Xpert MTB/RIF-based algorithms using a non-randomised stepped-wedge design. PLOS One 2016;11(3):e0150487.
- Nair SA, Raizada N, Sachdeva KS, Denkinger C, Schumacher S, Dewan P, et al. Factors associated with tuberculosis and rifampicin-resistant tuberculosis amongst symptomatic patients in India: a retrospective analysis. PLOS One 2016;11(2):e0150054.
- Nansumba M, Kumbakumba E, Orikiriza P, Muller Y, Nackers F, Debeaudrap P, et al. Detection yield and tolerability of string test for diagnosis of childhood intrathoracic tuberculosis. Paediatric Infectious Disease Journal 2016;35(2):146-51.
- Nataprawira HM, Ruslianti V, Solek R, Hawani D, Mianti M, Anggraeni R, et al. Outcome of tuberculous meningitis in children: the first comprehensive retrospective cohort study in Indonesia. International Journal of Tuberculosis and Lung Disease 2016;20(7):909-14.
- NCT03831906. TB-Speed Pneumonia. (first received 6 February 2019).
- NCT04038632. TB-Speed Decentralisation Study. (first received 2 August 2019).
- Ncube RT, Takarinda KC, Zishiri C, den Boogaard W, Mlilo N, Chiteve C, et al. Age-stratified tuberculosis treatment outcomes in Zimbabwe: are we paying attention to the most vulnerable? Public Health Action 2017;7(3):212-7.
- Nduba V, Hoog AH, Mitchell E, Onyango P, Laserson K, Borgdorff M. Prevalence of tuberculosis in adolescents, western Kenya: implications for control programs. International Journal of Infectious Diseases 2015;35:11-7.
- Ngabonziza JC, Ssengooba W, Mutua F, Torrea G, Dushime A, Gasana M, et al. Diagnostic performance of smear microscopy and incremental yield of Xpert in detection of pulmonary tuberculosis in Rwanda. BMC Infectious Diseases 2016;16(1):660.
- Nicol M, Schumacher S, Workman L, Broger T, Baard C, Prins M, et al. Accuracy of a novel urine test, Fujifilm SILVAMP TB LAM, for the diagnosis of pulmonary tuberculosis in children. Clinical Infectious Diseases 2020;72(9):e280-8.
- Ntinginya EN, Squire SB, Millington KA, Mtafya B, Saathoff E, Heinrich N, et al. Performance of the Xpert® MTB/RIF assay in an active case-finding strategy: a pilot study from Tanzania. International Journal of Tuberculosis and Lung Disease 2012;16(11):1468-70.
- Opota O, Zakham F, Mazza-Stalder J, Nicod L, Greub G, Jaton K. Added value of Xpert MTB/RIF Ultra for diagnosis of pulmonary tuberculosis in a low-prevalence setting. Journal of Clinical Microbiology 2019;57(2):pii: e01717-18.
- Pandey P, Pant ND, Rijal KR, Shrestha B, Kattel S, Banjara MR, et al. Diagnostic accuracy of GeneXpert MTB/RIF assay in comparison to conventional drug susceptibility testing method for the diagnosis of multidrug-resistant tuberculosis. PLOS One 2017;12(1):e0169798.
- Pink F, Brown TJ, Kranzer K, Drobniewski F. Evaluation of Xpert MTB/RIF for detection of Mycobacterium tuberculosis in cerebrospinal fluid. Journal of Clinical Microbiology 2016;54(3):809-11.
- Planting NS, Visser GL, Nicol MP, Workman L, Isaacs W, Zar HJ. Safety and efficacy of induced sputum in young children hospitalised with suspected pulmonary tuberculosis. International Journal of Tuberculosis and Lung Disease 2014;18(1):8-12.
- Raizada N, Sachdeva KS, Nair SA, Kulsange S, Gupta RS, Thakur R, et al. Enhancing TB case detection: experience in offering upfront Xpert MTB/RIF testing to pediatric presumptive TB and DR TB cases for early rapid diagnosis of drug sensitive and drug resistant TB. PLOS One 2014;9(8):e105346.
- Raizada N, Sachdeva KS, Swaminathan S, Kulsange S, Khaparde SD, Nair SA, et al. Piloting upfront Xpert MTB/RIF testing on various specimens under programmatic conditions for diagnosis of TB & DR-TB in paediatric population. PLOS One 2015;10(10):e0140375.
- Raizada N, Sachdeva KS, Sreenivas A, Kulsange S, Gupta RS, Thakur R, et al. Catching the missing million: experiences in enhancing TB & DR-TB detection by providing upfront Xpert MTB/RIF testing for people living with HIV in India. PLOS One 2015;10(2):e0116721.
- Raizada N, Khaparde SD, Salhotra VS, Rao R, Kalra A, Swaminathan S, et al. Accelerating access to quality TB care for pediatric TB cases through better diagnostic strategy in four major cities of India. PLOS One 2018;13(2):e0193194.
- Raizada N, Khaparde SD, Rao R, Kalra A, Sarin S, Salhotra VS, et al. Upfront Xpert MTB/RIF testing on various specimen types for presumptive infant TB cases for early and appropriate treatment initiation. PLOS One 2018;13(8):e0202085.
- Rathour JS, Mantan M, Khanna A, et al. Evaluation of GENE XPERT assay in extrapulmonary tuberculosis in children. Journal of Evolution of Medical and Dental Sciences 2019;8(1):76-80.
- Rebecca B, Chacko A, Verghese V, Rose W. Spectrum of pediatric tuberculosis in a tertiary care setting in South India. Journal of Tropical Pediatrics 2018;64(6):544-7.
- Rivera VR, Jean-Juste MA, Gluck SC, Reeder HT, Sainristil J, Julma P, et al. Diagnostic yield of active case finding for tuberculosis and HIV at the household level in slums in Haiti. International Journal of Tuberculosis and Lung Disease 2017;21(11):1140-6.
- Sabi I, Kabyemera R, Mshana SE, Kidenya BR, Kasanga G, Gerwing-Adima LE, et al. Pulmonary TB bacteriologically confirmed by induced sputum among children at Bugando Medical Centre, Tanzania. International Journal of Tuberculosis and Lung Disease 2016;20(2):228-34.
- Sachdeva KS, Raizada N, Sreenivas A, Van't Hoog AH, den Hof S, Dewan PK, et al. Use of Xpert MTB/RIF in decentralized public health settings and its effect on pulmonary TB and DR-TB case finding in India. PLOS One 2015;10(5):e0126065.
- Sanchini A, Fiebig L, Drobniewski F, Haas W, Richter E, Katalinic-Jankovic V, et al. Laboratory diagnosis of paediatric tuberculosis in the European Union/European Economic Area: analysis of routine laboratory data, 2007 to 2011. Eurosurveillance 2014;19(11):pii: 20744.
- Sander MS, Laah SN, Titahong CN, Lele C, Kinge T, Jong BC, et al. Systematic screening for tuberculosis among hospital outpatients in Cameroon: the role of screening and testing algorithms to improve case detection. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases 2019;15:100095. [DOI: 10.1016/j.jctube.2019.100095]
- Sanjuan-Jimenez R, Toro-Peinado I, Bermudez P, Colmenero JD, Morata P. Comparative study of a real-time PCR assay targeting senX3-regX3 versus other molecular strategies commonly used in the diagnosis of tuberculosis. PLOS One 2015;10(11):e0143025.
- Schumacher SG, Smeden M, Dendukuri N, Joseph L, Nicol MP, Pai M, et al. Diagnostic test accuracy in childhood pulmonary tuberculosis: a Bayesian latent class analysis. American Journal of Epidemiology 2016;184(9):690-700.
- Scott LE, Beylis N, Nicol M, Nkuna G, Molapo S, Berrie L, et al. Diagnostic accuracy of Xpert MTB/RIF for extrapulmonary tuberculosis specimens: establishing a laboratory testing algorithm for South Africa. Journal of Clinical Microbiology 2014;52(6):1818-23.
- Shah I, Gupta Y. Xpert MTB/RIF for diagnosis of tuberculosis and drug resistance in Indian children. Indian Pediatrics 2016;53(9):837-8.
- Shah MA, Shah I. Increasing prevalence of pediatric drug-resistant tuberculosis in Mumbai, India, and its outcome. Pediatric Infectious Disease Journal 2018;37(12):1261-3.
- Shah I, Bhamre R, Shetty NS. Accuracy of Xpert® Mycobacterium tuberculosis/rifampicin assay in diagnosis of pulmonary tuberculosis. Infectious Diseases 2019;51(7):550-3.
- Sharma SK, Kohli M, Yadav RN, Chaubey J, Bhasin D, Sreenivas V, et al. Evaluating the diagnostic accuracy of Xpert MTB/RIF assay in pulmonary tuberculosis. PLOS One 2015;10(10):e0141011.
- Sieiro TL, Aurílio RB, Soares EC, Chiang SS, Sant Anna CC. The role of the Xpert MTB/RIF assay among adolescents suspected of pulmonary tuberculosis in Rio de Janeiro, Brazil. Revista da Sociedade Brasileira de Medicina Tropical 2018;51(2):234-6.
- Singh S, Singh A, Prajapati S, Kabra SK, Lodha R, Mukherjee A, et al. Xpert MTB/RIF assay can be used on archived gastric aspirate and induced sputum samples for sensitive diagnosis of paediatric tuberculosis. BMC Microbiology 2015;15:191.
- Singh UB, Pandey P, Mehta G, Bhatnagar AK, Mohan A, Goyal V, et al. Genotypic, phenotypic and clinical validation of GeneXpert in extra-pulmonary and pulmonary tuberculosis in India. PLOS One 2016;11(2):e0149258.
- Solomons RS, Visser DH, Marais BJ, Schoeman JF, Furth AM. Diagnostic accuracy of a uniform research case definition for TBM in children: a prospective study. International Journal of Tuberculosis and Lung Disease 2016;20(7):903-8.
- Sun L, Qi X, Liu F, Wu X, Yin Q, Guo Y, et al. A test for more accurate diagnosis of pulmonary tuberculosis. Pediatrics November 2019;144(5):e20190262.
- Sureshbabu R, Lakshmi Murali A, Palaniswamy M. Molecular diagnosis of drug resistance tuberculosis in the Districts Of Tamilnadu. International Journal of Pharma and Bio Sciences 2016;7(4):B42-B6.
- Tadesse M, Abebe G, Abdissa K, Aragaw D, Abdella K, Bekele A, et al. GeneXpert MTB/RIF Assay for the diagnosis of tuberculous lymphadenitis on concentrated fine needle aspirates in high tuberculosis burden settings. PLOS One 2015;10(9):e0137471.
- Tafur KT, Coit J, Leon SR, Pinedo C, Chiang SS, Contreras C, et al. Feasibility of the string test for tuberculosis diagnosis in children between 4 and 14 years old. BMC Infectious Diseases 2018;18:574.
- Tang T, Liu F, Lu X, Huang Q. Evaluation of GeneXpert MTB/RIF for detecting Mycobacterium tuberculosis in a hospital in China. Journal of International Medical Research 2017;45(2):816-22.
- Theron G, Peter J, Zyl-Smit R, Mishra H, Streicher E, Murray S, et al. Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting. American Journal of Respiratory and Critical Care Medicine 2011;184(1):132-40.
- Triasih R, Robertson C, Duke T, Graham SM. Risk of infection and disease with Mycobacterium tuberculosis among children identified through prospective community-based contact screening in Indonesia. Tropical Medicine & International Health 2015;20(6):737-43.
- Ullah I, Javaid A, Masud H, Ali M, Basit A, Ahmad W, et al. Rapid detection of Mycobacterium tuberculosis and rifampicin resistance in extrapulmonary tuberculosis and sputum smear negative pulmonary suspects using Xpert MTB/RIF. Journal of Medical Microbiology 2017;66(4):412-8.
- Walters E, Gie RP, Hesseling AC, Friedrich SO, Diacon AH, Gie RP. Rapid diagnosis of pediatric intrathoracic tuberculosis from stool samples using the Xpert MTB/RIF assay: a pilot study. Pediatric Infectious Disease Journal 2012;31(12):1316.
- Walters E, Demers AM, Zalm MM, Whitelaw A, Palmer M, Bosch C, et al. Stool culture for diagnosis of pulmonary tuberculosis in children. Journal of Clinical Microbiology 2017;55(12):3355-65.
- Walters E, Zalm MM, Demers AM, Whitelaw A, Palmer M, Bosch C, et al. Specimen pooling as a diagnostic strategy for microbiologic confirmation in children with intrathoracic tuberculosis. Paediatric Infectious Disease Journal 2018;38(6):e128-31.
- Wang G, Wang S, Yang X, Sun Q, Jiang G, Huang M, et al. Accuracy of Xpert MTB/RIF Ultra for the diagnosis of pleural TB in a multicenter cohort study. Chest 2020;157(2):268-275.
- Yadav R, Vaidya P, Mathew JL, Singh S, Khaneja R, Agarwal P, et al. Diagnostic accuracy of Xpert MTB/RIF ultra for detection of Mycobacterium tuberculosis in children: a prospective cohort study. Letters in Applied Microbiology 2021;72(3):225-30.
- Zhang AM, Li F, Liu XH, Xia L, Lu SH. Application of Gene Xpert Mycobacterium tuberculosis DNA and resistance to rifampicin assay in the rapid detection of tuberculosis in children. Zhonghua er ke za zhi [Chinese Journal of Pediatrics] 2016;54(5):370-4.
- ChiCTR1800015075. Diagnostic accuracy of Xpert MTB/RIF Ultra assay on diagnosing pediatric pulmonary tuberculosis. (first received 6 March 2018). [ChiCTR1800015075]
- Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology 2011;64(4):401-6.
- Bjerrum S, Schiller I, Dendukuri N, Kohli M, Nathavitharana RR, Zwerling AA, et al. Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV. Cochrane Database of Systematic Reviews 2019;10(10):CD011420.
- Branigan, D. Tuberculosis Diagnostics Pipeline report 2021. (accessed 17 December 2021).
- Broger T, Sosse B, Du Toit E, Kerkhoff AD, Schutz C, Reipold EI, et al. Novel lipoarabinomannan point-of-care tuberculosis test for people with HIV: a diagnostic accuracy study. Lancet Infectious Diseases 2019;19(8):852-61.
- Cepheid. Brochure: Xpert® MTB/RIF Ultra. (accessed 3 November 2021).
- Chakravorty S, Simmons AM, Rowneki M, Parmar H, Cao Y, Ryan J, et al. The new Xpert MTB/RIF Ultra: improving detection of Mycobacterium tuberculosis and resistance to rifampin in an assay suitable for point-of-care testing. mBio 2017;8(4):1-12.
- Chiang SS, Swanson DS, Starke JR. New diagnostics for childhood tuberculosis. Infectious Disease Clinics of North America 2015;29(3):477-502.
- Chu H, Cole SR. Bivariate meta-analysis of sensitivity and specificity with sparse data: a generalized linear mixed model approach. Journal of Clinical Epidemiology 2006;59(12):1331-2.
- Covidence. Melbourne, Australia: Veritas Health Innovation, (accessed 1 October 2021). Available at .
- Cruz AT, Revell PA, Starke JR. Gastric aspirate yield for children with suspected pulmonary tuberculosis. Journal of the Pediatric Infectious Diseases Society 2012;2(2):171-4.
- David SG, Lovero KL, Pombo-March MF, Abreu TG, Ruffino-Netto A, Kritski AL, et al. A comparison of tuberculosis diagnostic systems in a retrospective cohort of HIV-infected children in Rio de Janeiro, Brazil. International Journal of Infectious Diseases 2017;59:150-5.
- Dodd PJ, Yuen CM, Sismanidis C, Seddon JA, Jenkins HE. The global burden of tuberculosis mortality in children: a mathematical modelling study. Lancet Global Health 2017;5(9):e898-906.
- Dorman SE, Schumacher SG, Alland D, Nabeta P, Armstrong DT, King B, et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infectious Diseases 2018;18(1):76-84.
- Dunn JJ, Starke JR, Revell PA. Laboratory diagnosis of Mycobacterium tuberculosis infection and disease in children. Journal of Clinical Microbiology 2016;54(6):1434-41.
- Frigati L, Maskew M, Workman L, Munro J, Andronikou S, Nicol MP, et al. Predictors of culture-confirmed pulmonary tuberculosis in children in a high tuberculosis and HIV prevalence area. Pediatric Infectious Disease Journal 2015;34(9):e206-10.
- Furin J. Advances in the diagnosis, treatment, and prevention of tuberculosis in children. Expert Review of Respiratory Medicine 2019;13(3):301-11.
- Garner P, Hopewell S, Chandler J, MacLehose H, Schünemann HJ, Akl EA, et al. When and how to update systematic reviews: consensus and checklist. BMJ 2016;354:i3507.
- Graham SM, Ahmed T, Amanullah F, Browning R, Cardenas V, Casenghi M, et al. Evaluation of tuberculosis diagnostics in children: 1. Proposed clinical case definitions for classification of intrathoracic tuberculosis disease. Consensus from an expert panel. Journal of Infectious Diseases 2012;205(Suppl 2):S199-208.
- Graham SM, Cuevas LE, Jean-Philippe P, Browning R, Casenghi M, Detjen AK. Clinical case definitions for classification of intrathoracic tuberculosis in children: an update. Clinical Infectious Diseases 2015;61(Suppl 3):S179-87.
- Harausz EP, Garcia-Prats AJ, Law S, Schaaf HS, Kredo T, Seddon JA, et al. Treatment and outcomes in children with multidrug-resistant tuberculosis: a systematic review and individual patient data meta-analysis. PLOS Medicine 2018;15(7):e1002591.
- Horne DJ, Kohli M, Zifodya JS, Schiller I, Dendukuri N, Tollefson D, et al. Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database of Systematic Reviews 2019;7(6):CD009593.
- Jenkins HE, Yuen CM, Rodriguez CA, Nathavitharana RR, McLaughlin MM, Donald P, et al. Mortality in children diagnosed with tuberculosis: a systematic review and meta-analysis. Lancet Infectious Diseases 2017;17(3):285-95.
- Kohli M, Schiller I, Dendukuri N, Yao M, Dheda K, Denkinger CM, et al. Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database of Systematic Reviews 2021, Issue 1. Art. No: CD012768. [DOI: 10.1002/14651858.CD012768.pub3]
- Kunkel A, Abel Zur Wiesch P, Nathavitharana RR, Marx FM, Jenkins HE, Cohen T. Smear positivity in paediatric and adult tuberculosis: systematic review and meta-analysis. BMC Infectious Diseases 2016;16(282):1-9.
- Macaskill P, Gatsonis C, Deeks JJ, Harbord RM, Takwoingi Y. Chapter 10. Analysing and presenting results. In: Deeks JJ, Bossuyt PM, Gatsonis C, editor(s). Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 1.0.0. Cochrane, 2013. Available from .
- MacLean E, Sulis G, Denkinger CM, Johnston JC, Pai M, Khana FA. Diagnostic accuracy of stool Xpert MTB/RIF for detection of pulmonary tuberculosis in children: a systematic review and meta-analysis. Journal of Clinical Microbiology 2019;57(6):e02057-18.
- Marais BJ, Gie RP, Schaaf HS, Hesseling AC, Obihara CC, Starke JJ, et al. The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era. International Journal of Tuberculosis and Lung Disease 2004;8(4):392-402.
- Marais BJ, Gie RP, Obihara CC, Hesseling AC, Schaaf HS, Beyers N. Well defined symptoms are of value in the diagnosis of childhood pulmonary tuberculosis. Archives of Disease in Children 2005;90(11):1162-5.
- Marais BJ, Gie RP, Schaaf HS, Hesseling AS, Enarson DA, Beyers N. The spectrum of disease in children treated for tuberculosis in a highly endemic area. International Journal of Tuberculosis and Lung Disease 2006;10:732–8.
- Marais BJ, Gie RP, Hesseling AC, Schaaf HS, Enarson DA, Beyers N. The bacteriologic yield in children with intrathoracic tuberculosis. Clinical Infectious Diseases 2006;42:69-71.
- Marais BJ, Gie RP, Hesseling AC, Schaaf HS, Enarson DA, Beyers N. Radiographic signs and symptoms in children treated for tuberculosis: possible implications for symptom-based screening in resource-limited settings. Pediatric Infectious Disease Journal 2006;25(3):237-40.
- Marais BJ, Gie RP, Hesseling AC, Schaaf HS, Lombard C, Enarson DA, et al. A refined symptom-based approach to diagnose pulmonary tuberculosis in children. Pediatrics 2006;118(5):e1350-9.
- Marais BJ, Wright CA, Schaaf HS, Gie RP, Hesseling AC, Enarson DA, et al. Tuberculous lymphadenitis as a cause of persistent cervical lymphadenopathy in children from a tuberculosis-endemic area. Pediatric Infectious Disease Journal 2006;25(2):142-6.
- Marais BJ, Schaaf HS. Tuberculosis in children. Cold Spring Harbor Perspectives in Medicine 2014;4:1-21.
- Marais S, Thwaites G, Schoeman JF, Török ME, Misra UK, Prasad K, et al. Tuberculous meningitis: a uniform case definition for use in clinical research. Lancet Infectious Diseases 2010;10(11):803-12.
- Mishra H, Reeve BW, Palmer Z, Caldwell J, Dolby T, Naidoo CC, et al. Xpert MTB/RIF Ultra and Xpert MTB/RIF for diagnosis of tuberculosis in an HIV-endemic setting with a high burden of previous tuberculosis: a two-cohort diagnostic accuracy study. Lancet Respiratory Medicine 2020;8(4):368-82.
- Nathavitharana RR, Lederer P, Chaplin M, Bjerrum S, Steingart KR, Shah M. Impact of diagnostic strategies for tuberculosis using lateral flow urine lipoarabinomannan assay in people living with HIV. Cochrane Database of Systematic Reviews 2021, Issue 8. Art. No: CD014641. [DOI: 10.1002/14651858.CD014641]
- Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Statistics in Medicine 1998;17(8):873-90.
- Nicol MP, Allen V, Workman L, Isaacs W, Munro J, Pienaar S, et al. Urine lipoarabinomannan testing for diagnosis of pulmonary tuberculosis in children: a prospective study. Lancet Global Health 2014;2(5):e278-84.
- Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. [DOI: 10.1371/journal.pmed1000097]
- Reid MJ, Saito S, Fayorsey R, Carter RJ, Abrams EJ. Assessing capacity for diagnosing tuberculosis in children in sub-Saharan African HIV care settings. International Journal of Tuberculosis and Lung Disease 2012;16(7):924-7.
- Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. Journal of Clinical Epidemiology 2005;58:982-90.
- Review Manager (RevMan). Version 5.4. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2020.
- Schünemann HJ, Oxman AD, Brozek J, Glasziou P, Jaeschke R, Vist GE, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 2008;336(7653):1106-10.
- Schünemann HJ, Mustafa R, Brozek J, Santesso N, Alonso-Coello P, Guyatt G, et al. GRADE Working Group. GRADE Guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health. Journal of Clinical Epidemiology 2016;76:89-98. [DOI: 10.1016/j.jclinepi.2016.01.032]
- Schünemann HJ, Mustafa R, Brozek J, Steingart KR, Leeflang M, Murad MH, et al. GRADE guidelines: 21 part 1. Study design, risk of bias and indirectness in rating the certainty across a body of evidence for test accuracy. Journal of Clinical Epidemiology 2020;122:129-41.
- Schünemann HJ, Mustafa R, Brozek J, Steingart KR, Leeflang M, Murad MH, et al. GRADE guidelines: 21 part 2. Inconsistency, Imprecision, publication bias and other domains for rating the certainty of evidence for test accuracy and presenting it in evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2020;122:142-52.
- Shah M, Hanrahan C, Wang ZY, Dendukuri N, Lawn SD, Denkinger CM, et al. Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults. Cochrane Database of Systematic Reviews 2016, Issue 5. Art. No: CD011420. [DOI: 10.1002/14651858.CD011420.pub2]
- Signorino C, Votto M, De Filippo M, Marseglia GL, Galli L, Chiappini E. Diagnostic accuracy of Xpert ultra for childhood tuberculosis: a preliminary systematic review and meta-analysis. Pediatric Allergy and Immunology 2022;33 Suppl 27:80-82:80-82.
- Stata Statistical Software. StataCorp, Version 16. College Station: StataCorp LP, 2019.
- Takwoingi Y, Guo B, Riley RD, Deeks JJ. Performance of methods for meta-analysis of diagnostic test accuracy with few studies or sparse data. Statistical Methods in Medical Research 2015;0:1-19.
- Theart AC, Marais BJ, Gie RP, Hesseling AC, Beyers N. Criteria used for the diagnosis of childhood tuberculosis at primary health care level in a high-burden, urban setting. International Journal of Tuberculosis and Lung Disease 2005;9(11):1210-4.
- Wademan DT, Busakwe L, Nicholson TJ, Zalm M, Palmer M, Workman J, et al. Acceptability of a first-line anti-tuberculosis formulation for children: qualitative data from the SHINE trial. International Journal of Tuberculosis and Lung Disease 2019;12:1263-8.
- Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of Internal Medicine 2011;155(8):529-36.
- World Health Organization. Xpert MTB/RIF implementation manual. Technical and operational 'how-to' practical considerations. 2014 (accessed prior to 29 April 2019).
- World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis – rapid diagnostics for tuberculosis detection, 2021 update. Licence: CC BY-NC-SA 3.0 IGO. (accessed 12 October 2021).
- World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment – drug-resistant tuberculosis treatment, June 2020. (accessed 3 November 2021).
- World Health Organization. WHO consolidated guidelines on tuberculosis. Module 5: management of tuberculosis in children and adolescents. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO. (accessed 29 April 2022).
- World Health Organization. Global tuberculosis report 2021. (accessed 18 October 2021).
- World Health Organization. WHO operational handbook on tuberculosis. Module 3: diagnosis - rapid diagnostics for tuberculosis detection, 2021 update. Licence: CC BY-NC-SA 3.0 IGO. (accessed 2 November 2021).
- Zar HJ, Hanslo D, Apolles P, Swingler G, Hussey G. Induced sputum versus gastric lavage for microbiological confirmation of pulmonary tuberculosis in infants and young children: a prospective study. Lancet 2005;365(9454):130-4.
- Zar HJ, Workman L, Isaacs W, Munro J, Black F, Eley B, et al. Rapid molecular diagnosis of pulmonary tuberculosis in children using nasopharyngeal specimens. Clinical Infectious Diseases 2012;55(8):1088-95.
- Zhang M, Xue M, He JQ. Diagnostic accuracy of the new Xpert MTB/RIF Ultra for tuberculosis disease: a preliminary systematic review and meta-analysis. International Journal of Infectious Diseases 2020;90:35-45.
- Zifodya JS, Kreniske JS, Schiller I, Kohli M, Dendukuri N, Schumacher SG, et al. Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis. Cochrane Database of Systematic Reviews 2021, Issue 2. Art. No: CD009593. [DOI: 10.1002/14651858.CD009593.pub5]
- Kay AW, González Fernández L, Takwoingi Y, Eisenhut M, Vu RD, Steingart KR, Detjen AK, Mandalakas AM. Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for active tuberculosis and rifampicin resistance in children. Cochrane Database of Systematic Reviews 2020, Issue 8. Art. No: CD013359. [DOI: 10.1002/14651858.CD013359]
Source: PubMed